Lipocalin-2 as a Biomarker for Pneumococcal Infection Status and Uses Thereof
A method for determining the pneumococcal infection status of a subject, comprising the steps of: i, providing a biological sample obtained from a subject: ii. determining the level of lipocalin-2 in the biological sample; and iii. comparing the level determined in (ii) with one or more pre-determined reference values.
1 . A method for determining the pneumococcal infection status of a subject, comprising the steps of:
i. providing a biological sample obtained from a subject;
ii. determining the level of lipocalin-2 in the biological sample; and
iii. comparing the level determined in (ii) with one or more pre-determined reference values.
2 . A method for determining the pneumococcal infection status or malarial infection status of a subject, comprising the steps of:
i. providing a biological sample obtained from a subject;
ii. determining the level of lipocalin-2 and haptoglobin in the biological sample; and
iii. comparing the level determined in (ii) with one or more pre-determined reference values.
3 . A method according to claim 2 , wherein the method distinguishes severe pneumonia/pneumococcal infection from malarial infection.
4 . A method according to any one of claims 1 to 3 , wherein the biological sample is a plasma sample.
5 . A method according to claim 1 , wherein a level of lipocalin-2 greater than a concentration of 118 ng/mL is indicative of severe pneumonia or severe pneumococcal infection.
6 . A method according to any one of claim 1 or 5 , comprising determining the level of C-reactive protein and/or von Willebrand factor (vWF) in a biological sample from a subject and comparing the level of C-reactive protein and/or vWF with one or more pre-determined reference values.
7 . A method according to claim 6 , wherein a level of C-reactive protein greater than a concentration of 157 mg/mL is indicative of severe pneumonia or severe pneumococcal infection.
8 . A method according to claim 6 , wherein a level of vWF greater than a concentration of 1,915 mU/mL is indicative of severe pneumonia or severe pneumococcal infection.
9 . A method according to claim 2 , wherein a concentration of lipocalin-2 greater than about 98.64 ng/mL is indicative of acute respiratory distress and a concentration of haptoglobin greater than about 666,120 ng/mL is indicative of pneumonia as the cause of respiratory distress.
10 . A method according to claim 2 , wherein a concentration of lipocalin-2 greater than about 98.64 ng/mL is indicative of respiratory distress and a concentration of haptoglobin lower than about 627,000 ng/mL is indicative of malaria as the cause of respiratory distress.
11 . A method for determining the appropriate treatment for a subject comprising the steps of:
(a) providing a biological sample obtained from a subject;
(b) determining the level of lipocalin-2 in the biological sample from said subject;
(c) comparing the level of lipocalin-2 determined in step (b) with one or more predetermined reference values; and
(d) using the results in (c) to determine the most appropriate therapy.
12 . A method for determining the appropriate treatment for a subject comprising the steps of:
(a) providing a biological sample obtained from a subject;
(b) determining the level of lipocalin-2 and haptoglobin in the biological sample from said subject;
(c) comparing the level of lipocalin-2 and haptoglobin determined in step (b) with one or more predetermined reference values; and
(d) using the results in (c) to determine the most appropriate therapy.
13 . A method of determining the severity of a pneumococcal infection or the response of a pneumococcal infection to a particular treatment in a subject comprising the steps of:
(a) providing a biological sample obtained from a subject;
(b) determining the level of lipocalin-2 in the biological sample from said subject; and
(c) comparing the level of lipocalin-2 determined in step (b) with one or more reference values.
14 . A method of determining the severity of a malarial infection or pneumococcal infection or the response of a malarial infection or a pneumococcal infection to a particular treatment in a subject comprising the steps of:
(a) providing a biological sample obtained from a subject;
(b) determining the level of lipocalin-2 and haptoglobin in the biological sample from said subject; and
(c) comparing the level of lipocalin-2 and haptoglobin determined in step (b) with one or more reference value.
15 . A kit for use in determining the diagnosis of severe/very severe pneumonia and/or severe/very severe pneumococcal infection in a subject comprising at least one agent for determining the level of lipocalin-2, in a biological sample provided by the subject.
16 . A kit according to claim 15 comprising one or more agents for determining the level of one or more of C-reactive protein and/or vWF.
17 . A kit for use in determining the diagnosis of severe malaria or severe pneumococcal infection/severe pneumonia in a subject comprising at least one agent for determining the level of lipocalin-2 and haptoglobin in a biological sample provided by the subject.
18 . Use of the level of lipocalin-2, and optionally also one or more of C-reactive protein, vWF and/or haptoglobin, as a biomarker to determine the pneumococcal infection status of a subject.
19 . Use of the level of lipocalin-2 and haptoglobin as a biomarker to distinguish between a pneumococcal infection and a malarial infection of a subject with respiratory distress.
20 . Use of the level of lipocalin-2, C-reactive protein and/or vWF as a means of assessing the most appropriate therapy for an individual with a pneumococcal infection.
21 . Use of the level of lipocalin-2 and haptoglobin as a means of assessing the most appropriate therapy for an individual with a pneumococcal infection or malarial infection.
22 . A method for diagnosing pneumococcal infection in a patient comprising analysing a patient sample to determine the level of lipocalin-2, wherein pneumococcal infection is diagnosed if lipocalin-2 levels are elevated compared with one or more pre-determined reference values.
23 . The method of claim 22 wherein if the level of lipocalin-2 in the sample is greater than about 118 ng/mL this is diagnostic of pneumococcal/pneumonia infection.
24 . A method for diagnosing pneumococcal infection in a patient by analysing a patient sample to determine the level of lipocalin-2, and the level of one or more of C-reactive protein and von Willebrand factor (vWF), wherein pneumococcal infection is diagnosed if the level of lipocalin-2, and the level of one or more of C-reactive protein and von Willebrand factor is elevated compared with one or more pre-determined reference values.
25 . The method of claim 24 wherein if the level of lipocalin-2 in the sample is greater than about 118 ng/mL, the level of C-reactive protein is greater than about 157 mg/mL and/or the level of vWF is greater than about 1,915 mU/mL this is diagnostic of pneumococcal infection/pneumonia.
26 . A method for diagnosing and treating pneumococcal infection in a patient comprising: analysing a patient sample to determine the level of lipocalin-2, wherein pneumococcal infection is diagnosed if lipocalin-2 levels are elevated compared with one or more pre-determined reference values; and administering antibiotics or another therapy for pneumococcal infection, to a patient diagnosed with pneumococcal infection.
27 . The method of claim 26 wherein if the level of lipocalin-2 in the sample is greater than about 118 ng/mL this is diagnostic of pneumococcal/pneumonia infection.
28 . The method of claim 26 or 27 further comprising analysing a patient sample to determine the level of one or more of C-reactive protein and von Willebrand factor (vWF), wherein pneumococcal infection is diagnosed if the level of lipocalin-2, and the level of one or more of C-reactive protein and von Willebrand factor is elevated compared with one or more pre-determined reference values.
29 . The method of claim 28 wherein if the level of lipocalin-2 in the sample is greater than about 118 ng/mL, and the level of C-reactive protein is greater than about 157 mg/mL and/or the level of vWF is greater than about 1,915 mU/mL this is diagnostic of pneumococcal infection/pneumonia.
30 . A method for treating pneumococcal infection in a patient comprising: requesting a test to determine whether a patient has elevated levels of lipocalin-2 and administering antibiotics or another therapy for pneumococcal infection to a patient with levels of lipocalin-2 that are elevated compared to a reference value.
31 . A method for diagnosing pneumococcal infection in a subject, wherein the pneumococcal infection is characterised by the presence of elevated levels of lipocalin-2 comprising:
i) providing a biological sample obtained from the subject;
ii) applying an antibody, preferably a monoclonal antibody, specific for lipocalin-2 to the sample, wherein presence of lipocalin-2 creates an antibody-lipocalin-2 complex;
iii) applying a detection agent that detects the antibody-lipocalin-2 complex; and
iv) diagnosing pneumococcal infection where an increase in the detection agents of step iii) is detected compared to a reference value.
32 . The method of claim 31 wherein if the level of antibody-lipocalin-2 complex in the sample is greater than seen with a concentration of lipocalin-2 of about 118 ng/mL, then this is diagnostic of pneumococcal/pneumonia infection.
33 . The method of claim 31 or 32 further comprising applying one or more antibodies specific for the C-reactive protein and/or von Willebrand factor (vWF).
34 . A method for diagnosing malaria infection in a patient comprising analysing a patient sample to determine the level of lipocalin-2 and haptoglobin, wherein malaria infection is diagnosed if lipocalin-2 levels are greater than about 98.64 ng/mL and haptoglobin levels are lower than 627,000 ng/mL.
35 . A method for diagnosing pneumococcal infection in a patient comprising analysing a patient sample to determine the level of lipocalin-2 and haptoglobin, wherein pneumococcal infection is diagnosed if lipocalin-2 levels are greater than about 98.64 ng/mL and haptoglobin levels are greater than 666,120 ng/mL.
36 . A method substantially as herein described with reference to the examples and figures.
37 . A kit substantially as herein described with reference to the examples and figures.
38 . A use substantially as herein described with reference to the examples and figures.